Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis

Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Mesa Laboratories, Inc.
Mesa Laboratories, Inc. News
Mesa Laboratories, Inc. Quantitative Score

About Mesa Laboratories, Inc.
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Mesa Laboratories, Inc. Earnings & Revenue
Mesa Laboratories, Inc. Financials
Table Compare
Compare MLAB metrics with: | |||
---|---|---|---|
Earnings & Growth | MLAB | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | MLAB | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | MLAB | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | MLAB | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Mesa Laboratories, Inc. Income
Mesa Laboratories, Inc. Balance Sheet
Mesa Laboratories, Inc. Cash Flow
Mesa Laboratories, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Strong Buy |
Return on Equity | Strong Sell |
Return on Assets | Strong Sell |
Debt/Equity Ratio | Strong Sell |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Mesa Laboratories, Inc. Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 0.6400 |
Payment Date | Dividend | Frequency |
---|---|---|
2025-06-16 | 0.16 | Quarterly |
2025-03-17 | 0.16 | Quarterly |
2024-12-16 | 0.16 | Quarterly |
2024-09-16 | 0.16 | Quarterly |
2024-06-14 | 0.16 | Quarterly |
Mesa Laboratories, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Mesa Laboratories, Inc. Executives
Name | Role |
---|---|
Mr. Gary M. Owens | Chief Executive Officer, President & Director |
Mr. John V. Sakys CPA | Vice President, Chief Financial Officer & Chief Accounting Officer |
Mr. Brian David Archbold | Senior Vice President of Continuous Improvement |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Mr. Gary M. Owens | Chief Executive Officer, President & Director | Male | 1968 | 1.1M |
Mr. John V. Sakys CPA | Vice President, Chief Financial Officer & Chief Accounting Officer | Male | 1969 | 582.29K |
Mr. Brian David Archbold | Senior Vice President of Continuous Improvement | Male | 1975 | 513.64K |
Mesa Laboratories, Inc. Insider Trades
Date | 19 Mar |
Name | Owens Gary M |
Role | President and CEO |
Transaction | Acquired |
Type | M-Exempt |
Shares | 21000 |
Date | 19 Mar |
Name | Owens Gary M |
Role | President and CEO |
Transaction | Disposed |
Type | S-Sale |
Shares | 21000 |
Date | 19 Mar |
Name | Owens Gary M |
Role | President and CEO |
Transaction | Disposed |
Type | X-InTheMoney |
Shares | 21000 |
Date | 19 Nov |
Name | Sullivan John James |
Role | Director |
Transaction | Disposed |
Type | G-Gift |
Shares | 2000 |
Date | 27 Oct |
Name | Owens Gary M |
Role | President and CEO |
Transaction | Acquired |
Type | A-Award |
Shares | 11559 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
19 Mar | Owens Gary M | President and CEO | Acquired | M-Exempt | 21000 |
19 Mar | Owens Gary M | President and CEO | Disposed | S-Sale | 21000 |
19 Mar | Owens Gary M | President and CEO | Disposed | X-InTheMoney | 21000 |
19 Nov | Sullivan John James | Director | Disposed | G-Gift | 2000 |
27 Oct | Owens Gary M | President and CEO | Acquired | A-Award | 11559 |